CorMedix Inc. Common Stock (CRMD) Stock
NYSE · CRMD
7.82
Fundamentals
Market cap
$611.86M
Price / Earnings ratio
3.2x
Price / Sales ratio
1.3x
Price / Book ratio
1.3x
Return on assets
27.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
NeutralCRMDSeptember 7, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
CRMD

Zacks Investment Research
CorMedix (CRMD) Upgraded to Buy: Here's Why
NeutralCRMDAugust 31, 2026
Zacks Investment ResearchNeutral
CorMedix (CRMD) Upgraded to Buy: Here's Why
CRMD

Zacks Investment Research
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
NeutralCRMDAugust 20, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
CRMD

Zacks Investment Research
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
NeutralCRMDAugust 14, 2026
Zacks Investment ResearchNeutral
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CRMD
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
374M247M123M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
991M654M327M0
Revenue to Profit
2025$311.7M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$163.1M
Net incomeEarnings
EPS forecast
Actual EPS
$0.28
$0.19
Q2FY25
$0.57
$0.57
Q3FY25
$0.78
Q4FY25
$0.72
Q1FY26
$0.72
Q2FY26
The market is expecting earnings per share of $0.72 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
NeutralCRMDSeptember 7, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
CRMD

Zacks Investment Research
CorMedix (CRMD) Upgraded to Buy: Here's Why
NeutralCRMDAugust 31, 2026
Zacks Investment ResearchNeutral
CorMedix (CRMD) Upgraded to Buy: Here's Why
CRMD

Zacks Investment Research
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
NeutralCRMDAugust 20, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
CRMD

Zacks Investment Research
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
NeutralCRMDAugust 14, 2026
Zacks Investment ResearchNeutral
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CRMD

MarketBeat
CorMedix Q2 Earnings Call Highlights
NeutralCRMDAugust 13, 2026
MarketBeatNeutral
CorMedix Q2 Earnings Call Highlights
CRMD

Stocktwits
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
NeutralCRMDAugust 13, 2026
StocktwitsNeutral
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
CRMD

Zacks Investment Research
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
NeutralCRMDAugust 13, 2026
Zacks Investment ResearchNeutral
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
CRMD

Zacks Investment Research
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
NeutralCRMDJune 30, 2026
Zacks Investment ResearchNeutral
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CRMD

Zacks Investment Research
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
NeutralCRMDJune 30, 2026
Zacks Investment ResearchNeutral
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CRMD

Zacks Investment Research
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
NeutralCRMDJune 30, 2026
Zacks Investment ResearchNeutral
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CRMD
About CorMedix Inc. Common Stock
A biopharmaceutical / medical-device company developing therapies based on a proprietary molecule (taurolidine) aiming to treat serious infections/inflammatory conditions.
SectorHealthcare
IndustryBiotechnology
Employees191
CEOMr. Joseph Todisco MBA
IPO DateMar 25, 2010
HeadquartersParsippany, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph Todisco MBA | CEO & Chairman of the Board of Directors | 1976 |
| Ms. Elizabeth Masson-Hurlburt B.A. | Executive VP and Chief Operating & Commercial Officer | 1979 |
| Ms. Kaufman Beth Zelnick Esq. | EVP, Chief Legal and Compliance Officer & Corporate Secretary | 1961 |
| Ms. Susan Blum | EVP & Chief Financial Officer | 1973 |
| Ms. Beth Steinbrenner | SVP & Chief Human Resource Officer | — |
| Dr. Matthew T. David M.D. | EVP & Chief Business Officer | 1978 |
| Donna Ucci | Senior VP & Head of Global Quality | — |
| Dr. Tushar Mukherjee | Senior VP & Head of Technical Operations | — |
| Dr. Peter Sullivan BCOP, Pharm.D. | Senior Vice President of Market Access | — |
| Mr. Jared L. Crandon Pharm.D. | Executive Director of Clinical Portfolio Management | — |
Fundamentals
Valuation
Market cap$611.86M
Price-to-sales ratio1.31
Price-to-book value1.31
Price-earnings ratio3.20
Return on Equity50.00%
Return on Sales47.00%
Return on Assets27.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$2.36
Income Statement
Average volume891,320
EBITDA$212.71M
1 year high (52w)$13.02
1 year low (52w)$6.13
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$14.50
Est return
84.71%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.2 | +1.5 | -10.4 | -7.0 | ||||||||
| 2022 | -12.8 | +15.6 | +15.1 | -38.4 | -8.2 | +34.0 | +39.7 | -35.7 | -17.7 | +9.3 | +34.2 | -1.6 |
| 2023 | +3.8 | -8.8 | -3.7 | +14.1 | -6.1 | -20.3 | +13.3 | -5.1 | -10.4 | -1.7 | -4.4 | +12.2 |
| 2024 | -21.8 | +16.4 | +15.5 | +26.1 | -4.5 | -17.4 | +7.0 | +39.9 | +38.4 | +24.2 | -1.3 | -18.2 |
| 2025 | +24.9 | +5.1 | -35.8 | +51.4 | +25.8 | -3.0 | -1.0 | +27.4 | -20.6 | +0.7 | -15.0 | +18.8 |
| 2026 | -36.2 | -12.7 | -5.8 | +8.1 | +8.3 | -7.1 | -11.1 | +9.4 | -6.3 |



